Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | YAP1 | P46937 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13074864 | 1.00 | GPR119 (0.47) | GPR119KDM4EPKMNPC1RAB9A | |
| SCHEMBL12892167 | 0.88 | GPR119 (0.45) | GPR119KDM4EPKMNPC1RAB9A | |
| SCHEMBL10154230 | 0.86 | KEAP1 (0.46) | GPR119KDM4EPKMNPC1RAB9A | |
| SCHEMBL12892176 | 0.85 | NPC1 (0.46) | GPR119NPC1RAB9AUSP30KMT2A | |
| SCHEMBL10154297 | 0.81 | KDM4E (0.50) | GPR119KDM4EPKMNPC1RAB9A | |
| SCHEMBL8344750 | 0.78 | NPC1 (0.50) | GPR119NPC1RAB9AUSP30KMT2A | |
| SCHEMBL8345392 | 0.78 | GPR119 (0.52) | GPR119KDM4EPKM | |
| SCHEMBL8344165 | 0.77 | NPC1 (0.44) | GPR119KDM4EPKMNPC1RAB9A | |
| SCHEMBL8346699 | 0.77 | MAPT (0.46) | GPR119KDM4EPKMNPC1RAB9A | |
| SCHEMBL8345175 | 0.75 | GPR119 (0.47) | GPR119KDM4EPKMNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8110683-B2 | Piperidinyl compounds that selectively bind integrins | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-07 | — | — | US | disclosed |
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | DE CORTE BART | 2011-04-21 | — | — | US | disclosed |
| WO-2004020435-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | JANSSEN PHARMACEUTICA N.V. (BE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092528-A1 | PIPERIDINYL COMPOUNDS THAT SELECTIVELY BIND INTEGRINS | ITGB3, ITGAV, ITGA2B | GPR119 1579/4885KDM4E 3297/4885PKM 3959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.